Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects

A pharmacokinetics (PK)/pharmacodynamics (PD) study (EudraCT number 2015‐002966‐21) was conducted to investigate the biosimilarity of Pelmeg(®) (pegfilgrastim), a biosimilar to EU‐authorized Neulasta(®), which is used in the clinic for prevention of chemotherapy‐induced neutropenia. The single‐dose,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pharmacol Res Perspect
Main Authors: Roth, Karsten, Lehnick, Dirk, Wessels, Hendrik, Höfler, Josef, Gastl, Barbara, Jankowsky, Ruediger
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6691757/
https://ncbi.nlm.nih.gov/pubmed/31417680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.503
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares